(Reuters) – The US Supreme Court on Monday knocked out a lower court of justice that had revived hundreds of trials that accused Merck & Co. to not properly warn patients with debilitating femoral fractures as a result of taking their osteoporosis drug Fosamax.
The nine justice dealers unanimously directed the Philadelphia-based 3rd Circuit Court of Appeal to reconsider their decision so that the trials could continue, even though federal officials had rejected Merck when the company tried to add a warning to the Fosamax label on the fracture. risk
. In that case, the case was whether a pharmaceutical company could be held liable under state laws to not warn about a health risk associated with a drug in which the US Food and Drug Administration rejected a business proposal to add a warning label for the medicine to the risk.
Fosamax helps prevent and treat osteoporosis, a condition that can lead to bone fractures in women who have been through menopause. But it can increase the risk of fractures in the femur or just below the hip joint, which often requires surgical intervention.
Sales of Fosamax, which is also available as a generic drug, amounted to $ 209 million in 201